Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The European Medicines Agency (EMA) has today recommended the conditional marketing authorisation of the ChAdOx1 nCoV-19 coronavirus vaccine developed by the University of Oxford with its partner AstraZeneca. Distribution will begin across all 27 member states once the decision is ratified by the European Commission.

Nurse reaching for a ChAdOx1 vaccine vial
  • EMA recommends granting conditional marketing authorisation to prevent coronavirus disease in people from 18 years of age
  • Vaccine shown to be highly effective and safe, preventing hospitalisation or death from COVID-19
  • EMA joins regulators from 20 countries in 5 continents worldwide in recommending the use of the vaccine

The EMA has recommended that two standard doses of ChAdOx1 nCoV-19 be administered at a four-to 12-week interval in people aged 18 years and older. This dosing regimen was shown in clinical trials to be safe and effective in preventing symptomatic COVID-19, with no severe cases and no hospitalisations more than 14 days after the second dose.

Read the full article on the University of Oxford website

 

Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please visit the Oxford COVID-19 vaccine web hub or visit the COVID-19 trial website.

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Daily contact COVID-19 testing for students effective at controlling transmission in schools

A study by the University of Oxford has found that daily testing of secondary school students who were in contact with someone with COVID-19 was just as effective in controlling school transmission as the current 10-day contact isolation policy.

Urgent need for COVID-19 vaccine equity: UN-Oxford research

COVID-19 vaccine programmes are expected to cost poorer countries an additional 56.6% on health budgets, compared with just 0.8% on wealthy countries’ health expenditure, according to new data from the United Nations Development Programme (UNDP), the World Health Organisation (WHO) and the University of Oxford.